Protecting Patients from Deceptive Drug Ads Online Act

• Authority: United States Congress
• Parent authority: Federal government
• Jurisdiction: United States
• Collections: U.S. federal laws
• Most recent activity: Defunct
• Most recent activity date: 2025-01-03

Risk subdomain coverage

Good coverage — Comprehensive governance measures or mitigations with clear procedures relating to the risk subdomain are explicitly described.

• False or misleading information
• Disinformation, surveillance, and influence at scale
• Fraud, scams, and targeted manipulation
• Governance failure

Minimal coverage — Brief mention but no specific mitigations, recommendations or governance measures relating to the risk subdomain are described.

• Pollution of information ecosystem
• Overreliance and unsafe use
• AI possessing dangerous capabilities

All other risk subdomains had no coverage in this document.

Risk Coverage Summary

The document primarily addresses misinformation risks (3.1, 3.2) related to false or misleading drug communications on social media, with good coverage of malicious actor risks (4.1, 4.3) involving fraud and manipulation. It also addresses AI system capabilities (7.2) through authorization of AI-enhanced surveillance, and governance mechanisms (6.5) through regulatory frameworks. Coverage is concentrated in misinformation, fraud prevention, and regulatory oversight domains.

Sector coverage

Good coverage — Comprehensive governance measures or mitigations with clear procedures relating to the sector are explicitly described.

• Information
• Professional & Technical Services
• Health Care & Social Assistance

All other sectors had no coverage in this document.

Sectors Summary

The document primarily governs the Health Care and Social Assistance sector through regulation of prescription drug advertising and promotion by healthcare providers. It also significantly governs the Information sector by regulating social media platforms and influencers who promote drugs. The Professional and Technical Services sector is governed through requirements for telehealth providers.

Legislative Status

Hard Law

Legislative Status Summary

This is a binding federal statute enacted by the United States Congress that amends the Federal Food, Drug, and Cosmetic Act with mandatory obligations, civil penalties, and enforcement mechanisms administered by the Secretary of Health and Human Services and the FDA.

Actors

Proposer

• Entity Types: AI_Governance_Actor
• Entities: United States Congress
• Summary: The document is titled as an 'Act' and contains legislative language typical of Congressional legislation, including section numbering, amendments to existing federal law, and authorization of appropriations.

Target

• Entity Types: AI_Developer, AI_Deployer, AI_User
• Entities: social media influencers; health care providers; telehealth providers; drug manufacturers; social media platforms
• Summary: The Act explicitly targets social media influencers and healthcare providers who make false or misleading drug communications, telehealth providers who facilitate prescribing, drug manufacturers who make payments, and social media platforms where promotional content appears.

Enforcer

• Entity Types: AI_Governance_Actor
• Entities: Secretary of Health and Human Services; Food and Drug Administration (FDA); Federal Trade Commission (FTC); Office of Prescription Drug Promotion; Center for Drug Evaluation and Research; Advertising and Promotional Labeling Branch; Center for Biologics Evaluation and Research
• Summary: The Secretary of Health and Human Services is designated as the primary enforcement authority, with the FDA conducting market surveillance and enforcement actions. A joint task force with the FTC is established for coordination.

Monitor

• Entity Types: AI_Governance_Actor
• Entities: Secretary of Health and Human Services; Food and Drug Administration (FDA); Federal Trade Commission (FTC); Office of Prescription Drug Promotion; Congress
• Summary: The FDA is authorized to conduct market surveillance using AI-enhanced tools, with reporting requirements to Congress. The Secretary must publicly disclose enforcement actions and payment data.

AI Lifecycle Stages

Lifecycle stages covered by the documents, as defined in the OECD Framework for the Classification of AI Systems

• Collect and Process Data
• Deploy
• Operate and Monitor

AI Lifecycle Summary

The document primarily addresses the Deploy and Operate and Monitor stages of the AI lifecycle. It explicitly authorizes AI-enhanced market surveillance tools for monitoring drug promotions on social media platforms, indicating coverage of operational AI systems. The document does not substantially cover earlier lifecycle stages such as planning, data collection, or model building.

Technical Scope

Terms relating to technical scope that are mentioned or implicitly referenced in the document

No technical scope terms identified.

Technical Scope Summary

The document explicitly mentions AI applications in the context of market surveillance for monitoring drug promotions on social media. It does not define specific AI system types, models, or technical thresholds. The focus is on the application of AI tools for content analysis and monitoring rather than on AI system development or classification.